Misplaced Pages

This is an old revision of this page, as edited by Entranced98 (talk | contribs) at 02:57, 17 November 2023 (Importing Wikidata short description: "Chemical compound"). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Pegsunercept is a drug for the treatment of rheumatoid arthritis. As of January 2010, Phase II clinical trials have been completed. It is being developed by Amgen.

Similarly to etanercept, pegsunercept is a soluble tumor necrosis factor receptor. Pegsunercept is a PEGylated protein.

References

1. Clinical trial number NCT00037700 for "Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis" at ClinicalTrials.gov
2. Clinical trial number NCT00111423 for "Evaluating the Safety of Extended Treatment With Pegsunercept (PEG sTNF-RI)in Subjects With Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
3. ^ Furst DE, Fleischmann R, Kopp E, Schiff M, Edwards C, Solinger A, Macri M (December 2005). "A phase 2 dose-finding study of PEGylated recombinant methionyl human soluble tumor necrosis factor type I in patients with rheumatoid arthritis". The Journal of Rheumatology. 32 (12): 2303–10. PMID 16331754.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• TNF inhibitors
• Immunosuppressants
• Amgen
• Antineoplastic and immunomodulating drug stubs